Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Sickle Cell Disease Patient Reported Outcomes in Adult Participants Aged ≥18 Years of Age On and Off Hydroxyurea
Authors not listed
Sanguine Biosciences · 2022
Abstract
The purpose of this study is to learn more about painful crisis in people with Sickle Cell Disease. For this reason, Pfizer is conducting a study to understand how people with Sickle Cell Disease feel on a daily basis, treat these painful episodes including if they treat themselves at home or go to a doctor's office/emergency room, as well as the types of medications that are taken during these episodes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Anonymous. (2022). Sickle Cell Disease Patient Reported Outcomes in Adult Participants Aged ≥18 Years of Age On and Off Hydroxyurea. <em>Sanguine Biosciences</em>. https://clinicaltrials.gov/study/NCT06503458
Vancouver
Anonymous. Sickle Cell Disease Patient Reported Outcomes in Adult Participants Aged ≥18 Years of Age On and Off Hydroxyurea. Sanguine Biosciences. 2022.
BibTeX
@misc{anon2022Sickle,
title = {Sickle Cell Disease Patient Reported Outcomes in Adult Participants Aged ≥18 Years of Age On and Off Hydroxyurea},
author = {Anonymous},
journal = {Sanguine Biosciences},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Asklepion Pharmaceuticals, LLC 2025
Open access · US-GOV
A Phase III, Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study of Intravenous L-Citrulline in Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis in Children, Adolescents and Young Adults (6 to 21 Years)
Arctic Therapeutics 2025
Open access · US-GOV
A Phase 2a Multi-site, Randomized, Double-blind, Dose Escalated, Placebo Controlled Biomarker Study to Determine the Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI (Mild Cognitive Impairment) or Mild Dementia Due to Alzheimer's Disease (AD) Aged 50 to 85 Years
The Indonesian Biomedical Journal 2019
Open access · CC-BY
Relationship between Circulating Protein p53 and High Sensitivity C-Reactive Protein in Central Obesity Men with Inflammaging
AstraZeneca 2018
Open access · US-GOV
A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
Innovation in aging 2024
Open access · OA
CELL REJUVENATION AND DISEASE
AstraZeneca 2020
Open access · US-GOV